Daiichi wins appeal of $42 million US verdict in Enhertu patent case
米控訴裁がSeagenの抗体薬特許を無効と判断、Daiichiへの42 百万ドル判決を覆す
The U.S. Court of Appeals for the Federal Circuit overturned a jury verdict that invalidated Seagen's patent for the cancer drug Enhertu, ruling the patent failed to adequately describe the invention, and ordered Seagen to pay $42 million in damages. The ruling marks a major turning point in the patent dispute between Japan's Daiichi Sankyo and U.S.-based Seagen, a subsidiary of Pfizer.
米連邦巡回控訴裁判所は、がん治療薬「エンハーツ」に関するSeagenの特許が発明を十分記載していないとして無効と判断し、Seagenに42 百万ドルの損害賠償を命じた陪審評決を取り消した。判決により、日本の第一三共と米国のPfizer傘下Seagenの特許係争は大きな転換を迎えた
掲載元：掲載元：https://www.reuters.com/legal/litigation/daiichi-wins-appeal-42-million-us-verdict-enhertu-patent-case-2025-12-02/#:~:text=WASHINGTON%2C%20Dec%202%20%28Reuters%29%20,Enhertu%20violated%20Seagen%27s%20patent%20rights
